ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2021
Attributable deaths of liver cancer in China.
Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Persistent and widening geographic disparities in liver cancer mortality in China, 1987-2021: a 35-year analysis from a national perspective.Journal of the National Cancer Center · 2026Article
- China data on the burden of alcohol-associated liver cancer from 1990 to 2021: a systematic analysis from the global burden of disease study 2021.Ecancermedicalscience · 2026Article
- Predicting the prognosis of hepatocellular carcinoma after curative resection using a nomogram based on the ratio of prealbumin to platelet distribution width.Journal of gastrointestinal oncology · 2025Article
- Application of AI-assisted compressed sensing in high resolution Gd-EOB-DTPA-enhanced MRI during hepatobiliary phase at 5.0 T.Quantitative imaging in medicine and surgery · 2025Article
- Preparation and Evaluation of Hepatoma-Targeting Glycyrrhetinic Acid Composite Micelles Loaded with Curcumin.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Combining serum biomarkers and MRI radiomics to predict treatment outcome after thermal ablation in hepatocellular carcinoma.American journal of translational research · 2025Article
- Emerging roles of stress granules in liver diseases: a comprehensive review.Frontiers in cell and developmental biology · 2025Review
- Plasma methylated GNB4 and Riplet as a novel dual-marker panel for the detection of hepatocellular carcinoma.Epigenetics · 2024Article
- [Exploring the reasons for liver cancer occurrence still after long-term nucleos(t)ide analogue therapy in patients with chronic hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Review
- Attributable liver cancer deaths and disability-adjusted life years in China and worldwide: profiles and changing trends.Cancer biology & medicine · 2024Article
- Ten-eleven translocation-2-mediated macrophage activation promotes liver regeneration.Cell communication and signaling : CCS · 2024Article
- Downregulation of N4-acetylcytidine modification in myeloid cells attenuates immunotherapy and exacerbates hepatocellular carcinoma progression.British journal of cancer · 2024Article
- Cancer profiles in China and comparisons with the USA: a comprehensive analysis in the incidence, mortality, survival, staging, and attribution to risk factors.Science China. Life sciences · 2024Article
- Advancements in understanding mechanisms of hepatocellular carcinoma radiosensitivity: A comprehensive review.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
- TNFR2 is a potent prognostic biomarker for post-transplant lung metastasis in patients with hepatocellular carcinoma.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
- Burden of liver cancer: From epidemiology to prevention.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2022Article
- Current cancer burden in China: epidemiology, etiology, and prevention.Cancer biology & medicine · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThere is little information about contributions of the well-known risk factors to the liver cancer burden. We conducted a comparative study to estimate the liver cancer burden attributable to major risk factors.
methodsLiver cancer deaths for adults were estimated from 978 county-level surveillance points in China in 2014. Risk factors were identified from the International Agency for Research on Cancer and the World Cancer Research Fund International. Population attributable fraction (PAF) by age, sex, and province was calculated using multiple formulas.
resultsIn total, 72.4% of liver cancer deaths could be attributable to the studied risk factors. Hepatitis B virus (HBV) was responsible for the largest fraction of liver cancer burden in both genders (PAF=55.6% in males, PAF=46.5% in females). PAFs for liver cancer burden attributable to smoking (15.7%
conclusionsHBV still contributes to the majority of liver cancer burden than any other risk factors. Targeted preventive measures should be implemented based on the degree of contributions of risk factors to liver cancer deaths.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.